Pharmstandard OJSC specifies details on a possible acquisition

Pharmstandard OJSC specifies details on a possible acquisition

Moscow, 9 July 2013 - Pharmstandard OJSC (LSE: PHST IL, RTS: PHST RU) ("Pharmstandard" or the "Company") would like to inform that the target of a possible acquisition, which the Company is in advanced discussions on, is BEVER PHARMACEUTICAL PTE LTD (Singapore) ("Bever Pharma").

The Company is contemplating to acquire 100% of shares in Bever Pharma for USD630 million.

As indicated before, this acquisition will be subject to approval by the Company's shareholders at the extraordinary shareholder meeting which will take place on 17 August 2013.

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.